REGENXBIO (RGNX) Earnings Analysis

REGENXBIO (RGNX) next reports earnings on 2026-08-06, consensus EPS 0.12 USD. Last quarter (2026-05-14) it missed with EPS -1.72 USD vs -1.36 USD est (-26.5%). It has beaten estimates in 3/7 recent quarters (43%). Trailing P/E -1.82.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does RGNX next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate0.12 USD
Revenue estimate0.10B

RGNX earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-14-1.72 USD-1.36 USD-26.5%Miss
2026-03-05-1.3 USD-1.01 USD-28.7%Miss
2025-11-06-1.2 USD-1.38 USD+13%Beat
2025-08-07-1.38 USD-1.13 USD-22.1%Miss
2025-05-120.12 USD0.41 USD-70.7%Miss
2025-03-13-1.01 USD-1.27 USD+20.5%Beat
2024-08-01-1.05 USD-1.29 USD+18.6%Beat

Beat rate: 3/7 (43%) over reported quarters with consensus data.

RGNX valuation and analyst view

Trailing P/E-1.82
Trailing EPS-5.53162 USD
Price / book25.37
Dividend yield0.00%
Market cap0.53B
Analyst consensusBuy (14 buy / 5 hold / 1 sell)
Avg price target20.8 USD

Related research pages

Frequently asked questions

When is REGENXBIO (RGNX)'s next earnings date?

REGENXBIO is next scheduled to report on 2026-08-06, with a consensus EPS estimate of 0.12 USD and revenue estimate of 0.10B.

Did RGNX beat earnings last quarter?

In its 2026-05-14 report, RGNX posted EPS of -1.72 USD versus a -1.36 USD estimate — a miss of 26.5%.

What is RGNX's earnings track record?

Over the last 7 reported quarters with consensus data, RGNX beat estimates 3 times (43%).

What is RGNX's current P/E ratio and EPS?

RGNX trades at a trailing P/E of -1.82 on trailing EPS of -5.531624322880903 USD.

What do analysts rate RGNX?

Analyst consensus is "Buy" across 20 ratings (1 strong buy, 13 buy, 5 hold, 1 sell, 0 strong sell). Average 12-month price target: 20.8 USD.